NCT03281824已完成1 期
Open-Label, Dose Increase and Phase I Study of ALT-P7 to Determine Safety, Tolerability, Pharmacokinetics for HER2 Positive Metastatic Breast Cancer Patients Who Have Progressed on Previous Trastuzumab-Based Therapy
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 27
- 试验地点
- 2
- 主要终点
- DLT test
研究概览
简要总结
This open-label study assessed the safety, tolerability and pharmacokinetics of ALT-P7(HM2-Drug Conjugate) in patients with HER2-positive metastatic breast cancer who have progressed on previous Trastuzumab-based therapy. Patients received ALT-P7(0.3 mg/kg~5.4 mg/kg, 7 groups) intravenously on Day 1 of each 3-week cycle.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patient who voluntarily signed the agreement
- •Adult patients ≥ 19 years of age
- •Eastern Cooperative Oncology Group(ECOG) Performance status of 0 or 1
- •Appropriate organism function proven by the following laboratory test results
- •Absolute neutrophil count ≥ 1500 cells/mm³
- •Platelets ≥ 100,000 cells/mm³
- •Hemoglobin ≥ 9.0 g/dL
- •Patients can receive red blood cell transfusions at this level.
- •Creatinine ≤ 1.5 × Upper Limit of Normal(ULN)
- •Aspartate Transaminase(AST) and Alanine Transaminase(ALT) ≤ 2.5 × ULN
- •Alkaline phosphatase ≤ 2.5 × ULN
- •Patients with liver and/or bone metastases: AST and ALT ≤ 5 × ULN, Alkaline phosphatase ≤ 5 × ULN
- •Albumin ≥ 3.0 g/dL, Total bilirubin ≤ 2.0 mg/dL
- •International Normalized Ratio(INR) < 1.5 × ULN(Except when you are on therapeutic anticoagulation therapy)
- •It should be negative in serum pregnancy test in the case of pre-menopausal women and women who were menopausal for less than 12 months
- •In the case of a fertile woman, it should be negative in pregnancy test, and all men and women should use effective contraceptive methods while enrolled in this study. You must also agree to continue the contraception during the trial and up to 6 months after the last dose of the test
- •Those who are expected to understand and observe the clinical trial plan according to the tester's judgment
- •Those who voluntarily agreed to participate in this clinical trial and signed the agreement
排除标准
- •Criteria for disease
- •Previous history of intolerance to Trastuzumab including Grade 3-4 infusion reaction or hypersensitivity
- •Previous history of permanent discontinuation of Trastuzumab due to the toxicity
- •A person who has untreated or symptomatic brain metastasis, or brain metastasis requiring radiation, surgery or corticosteroid therapy to control the brain metastases within 4 weeks of the first administration
- •Current Grade ≥ 2 (according to National Cancer Institute(NCI) Common Terminology Criteria for Adverse Events(CTCAE) v4.03 of peripheral neuropathy
- •If the toxicity of the previous treatment is not recovered to baseline level or lower than Grade 1 except for hair loss and peripheral neuropathy
- •Hypercalcemia requiring bisphosphonate therapy (> 1.5 mmol/L ionized calcium or calcium > 12 mg/dL or corrected serum calcium > ULN) However, it is allowed if bisphosphonate has been used for bone metastasis
- •A person who has received clinical trial material, chemotherapy, hormone therapy, radiotherapy, immunotherapy or biological therapy within 3 weeks of the first administration. However, it is required a minimum of 2 weeks after surgery if stereotactic radiosurgery is performed
- •Previous history of exposure to the cumulative dose of anthracycline (Doxorubicin > 360 mg/m², Epirubicin > 600 mg/m²)
- •Criteria for cardio pulmonary function
- •Unstable ventricular arrhythmia requiring treatment
- •Previous history of symptomatic congestive heart failure (NYHA Class II-IV)
- •Previous history of myocardial infarction or unstable angina within 6 months
- •Cardiac troponin I ≥ 0.2 ng/mL
- •A person who has inadequate left ventricular ejection fraction(LVEF) within 3 weeks of the first administration, LVEF <50% by echocardiography or Multiple-gated Acquisition(MUGA)
- •A person who has severe dyspnea or pneumonia requiring continuous oxygen therapy
- •Common criteria
- •Pregnant or breastfeeding
- •A person who has undergone surgical operation or significant traumatic injury within 30 days before registration, or is expected to require surgical operation during the clinical trial
- •Previous history of malignant tumors other than breast cancer within 5 years prior to screening (patient who can participate: squamous cell and basal cell carcinoma of the skin, intraepithelial cancer of the cervix, thyroid papillary cancer, or if the tester considers that the risk of relapse is minimum(regard as full recovery) and the sponsor agrees with it)
- •A person who needs chronic corticosteroid therapy (≥ 10 mg/day prednisone or equivalent volume of other anti-inflammatory corticosteroids)
- •If the result of human immunodeficiency virus (HIV), active hepatitis B or hepatitis C is positive during screening
- •Patients with uncontrolled concomitant illnesses, including mental illness/social conditions, which may affect compliance with clinical trial procedures
结局指标
主要结局
DLT test
时间窗: 21 days after first administration
Determination of Maximum Tolerated Dose(MTD) and the dose level showing Dose Limiting Toxicity(DLT), or determination of Recommended Phase II Dose(RP2D) as an alternative to MTD establishment
次要结局
- Incidence of Treatment-Emergent Adverse Events(up to 4 weeks)
- Pharmacokinetics test(up to 4 weeks)
- Efficacy test(At the end of Cycle 2 (each cycle is 21 days))
- Immunogenicity test(up to 4 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)Urothelial CarcinomaBladder CancerNCT05524545ALX Oncology Inc.36
已完成
1 期
A Phase 1/2a Study of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected AdultsHIV/AIDSNCT03721510International AIDS Vaccine Initiative19
已完成
1 期
Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate CancerProstate NeoplasmsNCT00473746Janssen Research & Development, LLC66
已完成
2 期
Titrating-Dose of Lonafarnib in Combination With RitonavirChronic Delta HepatitisNCT02527707Eiger BioPharmaceuticals15
已完成
2 期
Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212CancerNCT01072175Novartis Pharmaceuticals430